Exploring the Active Compounds of Traditional Mongolian Medicine Baolier Capsule (BLEC) in Patients with Coronary Artery Disease (CAD) Based on Network Pharmacology Analysis, Molecular Docking and Experimental Validation

被引:1
|
作者
Wei, Mengqiu [1 ]
Li, Fengjin [2 ]
Guo, Kai [3 ,4 ]
Yang, Tianxiao [5 ]
机构
[1] Zhongshan City Peoples Hosp, Intens Care Unit, Zhongshan 528400, Peoples R China
[2] Fujian Med Univ, Longyan Affiliated Hosp 1, Dept Gynecol, Longyan 36400, Peoples R China
[3] Guangdong Second Prov Gen Hosp, Dept Cardiol, Guangzhou 510000, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Emergency, Guangzhou 510000, Peoples R China
[5] Shandong Univ, Zibo Cent Hosp, Dept Cardiol, Zibo 255000, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
coronary artery disease; Baolier capsule; traditional Mongolian medicine; network pharmacology; experimental validation; TANSHINONE IIA; ATTENUATES ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; DOWN-REGULATION; BETA-CAROTENE; NARINGENIN; INFLAMMATION; CHOLESTEROL; MICE;
D O I
10.2147/DDDT.S395207
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: Baolier Capsule (BLEC) is a Traditional Mongolian Medicine comprising fifteen herbs. This study aims to illustrate the synergistic mechanism of BLEC in the treatment of Coronary Artery Disease (CAD) by using network pharmacology method, molecular docking and experimental validation. Methods: Searching and screening the active ingredients of different herbs in BLEC and target genes related to CAD in multiple databases. Subsequently, Protein-Protein Interactions Network (PPI-Net), gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment were used to identify the key targets. AutoDock was used to verify the binding ability between the active ingredient and key target through molecular docking. Reverse Transcription-Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) was used to verify the effect of active ingredient of BLEC on the key target gene. Finally, effect of BLEC on the degree of blood lipids and atherosclerosis was validated by animal experiment. Results: There are 144 active components and 80 CAD-related targets that are identified in BLEC in the treatment of CAD. What is more, 8 core genes were obtained by clustering and topological analysis of PPI-Net. Further, GO and KEGG analysis showed that fluid shear stress and atherosclerosis are the key pathways for BLEC to treat CAD. These results were validated by molecular docking method. In vitro, active compounds of BLEC (Quercetin, luteolin, kaempferol, naringenin, tanshinone IIA, beta-carotene, 7-O-methylisomucronulatol, piperine, isorhamnetin and Xyloidone) can inhibit 8 core gene (AKT1, EGFR, FOS, MAPK1, MAPK14, STAT3, TP53 and VEGFA) expression. Moreover, BLEC not only improve blood lipid levels but also inhibit the development of atherosclerosis in ApoE-knockout mice. Conclusion: Our research first revealed the basic pharmacological effects and related mechanisms of in the treatment of CAD. The predicted results provide some theoretical support for BLEC or its important active ingredients to treat CAD.
引用
收藏
页码:459 / 476
页数:18
相关论文
共 43 条
  • [41] Effective materials and mechanisms study of Tibetan herbal medicine Lagotis integra W. W. Smith treating DSS-induced ulcerative colitis based on network pharmacology, molecular docking and experimental validation
    Wang, Xinhong
    Zhang, Chi
    Liu, Lin
    Zhong, Yuanhan
    Wang, Yujie
    Liu, Fangyuan
    Zhu, Jixiao
    Mu, Zejing
    Zhang, Shouwen
    Wang, Xiaomin
    Zhong, Guoyue
    Liang, Jian
    Zeng, Jinxiang
    JOURNAL OF ETHNOPHARMACOLOGY, 2023, 301 : 115800
  • [42] Uncovering the effects and molecular mechanism of Astragalus membranaceus (Fisch.) Bunge and its bioactive ingredients formononetin and calycosin against colon cancer: An integrated approach based on network pharmacology analysis coupled with experimental validation and molecular docking
    Hu, Yu
    Zhai, Wenjuan
    Tan, Duanling
    Chen, Haipeng
    Zhang, Guiyu
    Tan, Xuanjing
    Zheng, Yuting
    Gao, Wenhui
    Wei, Yijie
    Wu, Jinjun
    Yang, Xin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [43] Exploring the potential quality marker of traditional tibetan medicine Erigeron multiradiatus based on ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry analysis, network pharmacology, and experimental verification
    Hamamozhi, Amu
    Li, Jing
    Su, Xuyan
    Cai, Wenfu
    Zhao, Riza
    Zhang, Zhifeng
    PHARMACOGNOSY MAGAZINE, 2022, 18 (78) : 406 - 417